Longevity Without Hype

“Lowering LDL C does not mean every cardiovascular risk marker improved. In this study, Lp(a) increased in 62.9% of patients after statin therapy, with an average rise of 19.3%. That is not a trivial finding, especially because elevated Lp(a) is itself an independent cardiovascular risk factor. It is another reason to look beyond the LDL C number alone.”

Dr. Alo, you just acknowledged that HORIZON did not establish an LDL-C finding and that we need the full dataset before drawing conclusions. Yet now you are immediately telling people that the way to “treat Lp(a)” is to “get your LDL cholesterol below 40.” Where is the randomized outcomes evidence showing that an LDL-C target below 40 specifically neutralizes the cardiovascular risk associated with elevated Lp(a)? HORIZON certainly did not test that question. Lowering LDL-C in a person with elevated Lp(a) and sufficient overall cardiovascular risk can absolutely be appropriate because it reduces the patient’s modifiable ApoB-related risk. But that is not the same thing as treating the Lp(a) itself. Statins do not meaningfully lower Lp(a), and LDL-C below 40 is not a universal guideline target for everyone with elevated Lp(a). The 2026 ACC/AHA guideline treats elevated Lp(a) as a risk enhancing factor that can justify more intensive management of modifiable risk factors. Even for very high risk patients with established ASCVD, the guideline’s LDL-C goal is

Dr. Alo, that is not what Lp(a)HORIZON showed. You are taking a negative Lp(a) trial and turning it into a positive LDL trial.
HORIZON tested whether substantially lowering Lp(a) with pelacarsen would reduce cardiovascular events in people with established cardiovascular disease and elevated Lp(a). It did not meet its primary endpoint. Novartis specifically reported that substantially lowering Lp(a) did NOT translate into a statistically significant reduction in cardiovascular death, heart attack, stroke or urgent coronary revascularization. That is the result. The announcement does not establish that getting LDL-C below 40 mg/dL means “you are not going to have heart attacks, you’re not going to have strokes, you’re not going to die because of this.” That conclusion was not the hypothesis HORIZON randomized and tested. (Novartis) In fact, the participants were already receiving guideline-directed treatment, including lipid-lowering and antihypertensive therapy, and cardiovascular events still occurred. Until the full HORIZON data are released, we do not even have the detailed event rates and subgroup analyses needed to make many of the interpretations now being circulated. A failed Lp(a)-lowering outcome trial cannot simply be repackaged as proof that extremely low LDL-C protected everybody. If you want to claim LDL-C below 40 explains the negative result, show the prespecified HORIZON analysis demonstrating that. The topline results released by Novartis do not. (Novartis)
This is exactly why biomarkers and clinical outcomes need to be kept separate. Pelacarsen successfully changed the biomarker. The expected cardiovascular benefit did not follow. The scientifically responsible response is to examine why when the complete data are available, not turn a negative trial for one hypothesis into proof of a different hypothesis the trial was not designed to test.

If a study has never compared taking a pill while keeping poor habits against fixing those habits head to head, can we really assume a lower test number equals a healthier heart?
We know that statins are effective at reducing LDL cholesterol on a blood panel. However, achieving a lower lab result in a blood test is a laboratory measurement, not direct proof of improved cardiovascular health in real world conditions.
There is no controlled trial comparing people who take a statin while continuing to smoke, drink, eat poorly, remain inactive, or live with hypertension and insulin resistance against people who comprehensively correct those exact risk factors through nutrition, weight control, exercise, and metabolic improvement.
Without that head to head trial, lowering a blood number later in life does not prove that an individual is getting a true cardiovascular benefit.
What we do know is that fixing underlying lifestyle and metabolic risk factors is well proven to reduce cardiovascular risk. Building healthy habits early in life yields the greatest protection for long term heart health.
Statins lower a blood number. Lifestyle habits address the root drivers of health.
Before relying on a test result to tell the entire story, we need to look at the bigger picture.

Stephen, this is also where I have a problem with your podcast. You give people a huge platform to make very confident health claims, but too often there is nobody there challenging them or fact checking those claims in real time. 😢

The basic science about fibre and short chain fatty acids is legitimate. But saying they are “the most healing nutrient in all nature” or “the most anti inflammatory molecule” is not an established scientific fact. Then the conversation moves into autoimmune disease without clearly separating biological mechanisms from treatments actually proven to work in humans.

A guest saying something confidently does not make it evidence.

When millions of people are watching health content, the host has some responsibility to ask the next question: What human evidence proves that claim?

That question is missing far too often. ✔️🇨🇦❤️



https://www.facebook.com/share/v/1bNNW2pCbt/

Next time someone tells you mRNA vaccines were a brand-new technology invented and rushed out in 2020, show them the timeline.

COVID-19 mRNA vaccines were developed quickly. The underlying technology was not. Scientists had been studying RNA biology for decades, demonstrated protein production from injected mRNA in animals in 1990, investigated mRNA vaccines and cancer treatments through the 1990s and 2000s, and conducted human mRNA vaccine trials years before COVID-19 appeared.

There is an important distinction: the COVID-19 vaccines were new products. mRNA technology was not new. Decades of research are exactly what made rapid vaccine development possible when SARS-CoV-2 appeared.